half
centuri
ago
linu
paul
wrote
enzym
molecul
complementari
structur
activ
complex
reaction
catalyz
rather
enter
reaction
model
profound
impact
drug
design
structurebas
drug
design
usual
involv
conceptu
synthesi
molecul
shape
bind
surfac
highli
complementari
protein
receptor
enzym
bind
site
goal
achiev
high
bind
affin
select
drug
must
also
appropri
admet
properti
affin
first
step
affin
select
gener
improv
ensur
perfect
geometr
noncoval
interact
bind
site
crystal
structur
proteinligand
complex
suggest
structur
modif
better
occupi
hydrophob
pocket
modif
improv
potenc
millimolar
nanomolar
rang
help
lead
clinic
approv
compound
hiv
proteas
inhibitor
nelfinavir
kuntz
et
al
shown
small
molecul
affin
protein
bind
site
result
noncoval
interact
gener
peak
picomolar
correspond
bind
kcalmol
contrast
bind
constant
enzym
transit
state
correspond
averag
g
bind
kcalmol
kcalmolmani
order
magnitud
stronger
attribut
noncoval
factor
alon
earlier
studi
group
shown
data
point
gener
coval
partial
coval
bond
transit
state
enzymecatalyz
reaction
strength
bind
may
achiev
fulli
coval
bond
schiff
base
acylenzym
intermedi
format
partial
coval
bond
take
place
gener
acidbas
catalysi
interact
metal
cofactor
partial
share
electron
substrat
reactant
water
molecul
transit
state
har
strong
coval
interact
could
help
provid
high
potenc
need
earli
stage
drug
develop
tendenc
avoid
coval
drug
go
back
studi
earli
demonstr
hepatotox
result
coval
bind
compound
c
bromobenzen
acetaminophen
time
howev
mani
exampl
highli
success
coval
act
drug
market
proton
pump
inhibitor
omeprazol
relat
compound
entir
class
antibiot
toxic
attribut
coval
bind
inher
featur
interact
per
se
rather
result
specif
spectrum
offtarget
modif
may
made
drug
even
metabolit
drug
whose
primari
mechan
action
noncoval
advanc
chemic
biolog
along
bioinformat
data
analysi
method
increasingli
abl
unravel
coval
modif
toler
toxic
suggest
reevalu
role
coval
bind
drug
drug
lead
perspect
limit
achiev
noncoval
bind
enzymeinhibitor
complex
greater
affin
achiev
coval
bond
drug
receptor
discuss
select
exampl
coval
act
drug
present
comprehens
review
see
refer
well
opportun
futur
structurebas
design
advanc
molecular
model
screen
targetspecif
librari
drugreceptor
bind
discuss
term
equat
bind
sometim
refer
master
equat
solvent
encompass
desolv
ligand
receptor
upon
complex
format
often
involv
favor
remov
hydrophob
molecul
aqueou
solut
displac
water
molecul
would
otherwis
held
pocket
protein
int
interact
free
energi
involv
direct
contact
ligand
protein
includ
noncoval
interact
van
der
waal
interact
electrostat
interact
hydrogen
bond
improv
bind
gener
kcalmol
accord
studi
kuntz
et
al
case
exceed
maxim
noncoval
bind
kcalmol
includ
biotinavidin
biotinstreptavidin
complex
case
high
affin
believ
due
enhanc
hydrogenbond
cooper
among
thing
small
molecul
hostguest
complex
larg
affin
also
recent
report
conf
motion
repres
unfavor
term
conform
strain
entropi
loss
upon
complex
respect
two
factor
import
includ
calcul
difficult
quantifi
nevertheless
research
area
activ
perspect
rel
magnitud
limit
bind
discuss
focu
might
enhanc
order
lead
potent
compound
inhibit
therapeut
relev
target
previous
survey
aqueou
bind
constant
type
organ
protein
host
includ
cyclodextrin
variou
synthet
organ
host
albumin
antibodi
enzym
nonenzymat
drug
receptor
bind
constant
fall
three
region
figur
weakbind
mediumbind
strongbind
weakbind
region
correspond
bind
constant
decimolar
hundr
micromolar
rang
log
k
cover
cyclodextrin
synthet
host
bind
organ
guest
catalyt
antibodi
enzym
bind
substrat
albumin
bind
organ
ligand
mediumbind
region
correspond
bind
constant
micromolar
nanomolar
rang
log
k
contain
antibodyantigen
complex
includ
antibodysmal
molecul
antibodybiomolecul
complex
catalyt
antibodyt
transit
state
complex
receptordrug
complex
enzymeinhibitor
complex
strongbind
region
enzymet
complex
whose
profici
suggest
bind
constant
subpicomolar
rang
log
k
valu
shown
figur
rough
correl
log
k
found
complex
weakand
mediumbind
system
suggest
weak
medium
bind
strongli
influenc
desolv
hydrophob
surfac
bring
togeth
upon
bind
linear
fit
give
slope
correspond
valu
equat
noncoval
factor
includ
van
der
waal
hydrogen
bond
electrostat
interact
commonli
involv
bind
process
contribut
variat
much
order
magnitud
rough
correl
noncoval
interact
appear
achiev
upper
limit
associ
constant
k
limit
mind
sensibl
commerci
drug
prospect
drug
candid
reli
mere
noncoval
bind
interact
bind
strength
subnanomolar
nanomolar
rang
kuntz
et
al
survey
experiment
data
strongestbind
drug
inhibitor
receptor
enzym
refer
earlier
indic
bind
energi
small
molecul
increas
kcalmol
nonhydrogen
atom
kcalmol
maximum
affin
drug
inhibitor
receptor
enzym
ligand
contain
nonhydrogen
atom
bind
energi
increas
littl
kcalmol
bind
observ
case
case
kuntz
et
al
studi
bind
energi
kcalmol
less
analysi
domin
interact
suggest
van
der
waal
interact
solvat
desolv
contribut
bind
affin
across
entir
set
ligand
noteworthi
outlier
bound
unusu
strongli
includ
metal
ion
coval
attach
ligand
wellknown
complex
biotinavidin
addit
kcalmol
maximum
affin
k
drug
receptor
also
note
gilli
et
al
enzym
except
catalyst
evolv
natur
million
year
quantit
measur
enzym
catalysi
profici
defin
wolfenden
k
tx
figur
much
greater
expect
noncoval
interact
propos
except
bind
result
coval
partial
coval
bond
format
may
involv
format
intermedi
coval
bound
enzym
cofactor
proton
transfer
gener
acidbas
catalysi
possibl
lowbarri
hydrogen
bond
occur
transit
state
bond
metal
cation
transit
state
discuss
previou
public
noncoval
interact
like
contribut
kcalmol
bind
correspond
bind
constant
typic
small
molecul
bind
protein
twentyfour
wolfenden
enzym
known
profici
divid
two
group
use
divid
line
twentyon
enzym
profici
three
enzym
profici
literatur
survey
catalyt
mechan
twentyfour
enzym
show
catalysi
twentyon
enzym
profici
involv
partial
coval
bondbreak
bondform
process
often
gener
acidbas
catalysi
well
particip
metal
organ
cofactor
use
term
coval
bond
coval
catalysi
requir
irrevers
bind
format
partial
bond
catalysi
two
enzym
chorism
mutas
cyclophilin
profici
involv
hydrogen
bond
electrostat
interact
noncoval
natur
remain
enzym
carbon
anhydras
profici
involv
gener
acidbas
catalysi
metal
bind
demonstr
coval
catalysi
exclud
low
profici
class
real
limit
weak
coval
forc
necessari
achiev
modest
acceler
therein
survey
emphas
enzym
profici
alway
involv
type
coval
catalysi
coval
hypothesi
check
twentyfour
enzym
known
profici
tini
number
compar
ten
thousand
enzym
unknown
profici
establish
profici
enzym
twentyfour
k
uncat
valu
measur
wolfenden
use
estim
k
uncat
valu
relat
reaction
exampl
rate
amid
hydrolysi
glycolysi
fluctuat
across
small
rang
therefor
avail
k
uncat
valu
employ
estim
profici
enzym
catalyz
relat
reaction
method
profici
enzym
estim
result
show
enzym
profici
therefor
involv
coval
catalysi
bind
constant
antibodyantigen
complex
exclud
catalyt
antibodi
survey
enzymeinhibitor
complex
kuntz
studi
enzymet
complex
profici
estim
compar
result
shown
figur
natur
evolv
antibodi
show
micromolar
bind
constant
k
enzymeinhibitor
complex
exhibit
nanomolar
bind
constant
k
well
within
domain
noncoval
bind
enzymet
complex
achiev
femtomolar
bind
k
must
origin
coval
interact
kcalmol
dichotomi
noncoval
bind
antigen
antibodi
inhibitor
enzym
coval
bind
transit
state
enzym
appar
summari
profici
greater
signal
coval
partial
coval
catalysi
enzym
refer
coval
catalysi
includ
electrophil
catalysi
particip
metal
nucleophil
catalysi
schiff
base
format
gener
acid
base
catalysi
coval
particip
cofactor
enzym
perform
coval
catalysi
employ
differ
mechan
avail
aqueou
solut
profici
bind
affin
found
empir
usual
limit
noncoval
bind
compris
hydrogen
bond
electrostat
van
der
waal
interact
hydrophob
effect
develop
new
drug
cost
billion
dollar
take
almost
year
develop
approv
first
step
often
find
hit
druglik
molecul
detect
affin
clinic
relev
target
present
variou
strategi
find
hit
includ
use
natur
product
highthroughput
screen
virtual
screen
ration
design
combin
techniqu
second
step
optim
hit
gener
lead
compound
increas
affin
select
optim
hit
normal
improv
potenc
fold
correspond
kcalmol
bind
energi
optim
lead
compound
typic
expect
achiev
nanoto
picomolar
bind
affin
correspond
kcal
mol
bind
energi
valid
hit
around
micromolar
inhibitor
contribut
least
twothird
net
bind
energi
fulli
optim
lead
compound
ultim
import
find
highli
potent
hit
huge
druglik
compound
librari
built
within
compani
provid
chemic
vendor
allow
identif
subsequ
optim
nonefficaci
paramet
physic
admet
properti
drug
lead
compound
k
nmwithin
realm
strongest
noncoval
bind
consid
quit
good
consensu
advantag
exploit
coval
interact
search
subpicomolar
affin
answer
depend
upon
import
drug
resid
time
bind
site
gener
drug
exert
effect
bound
receptor
therefor
anyth
keep
bound
longer
seen
benefici
kinet
thermodynam
compon
kinet
thermodynam
simpl
onestep
bind
onestep
dissoci
mechan
relat
express
inhibit
equilibrium
constant
k
k
k
relat
occup
time
drug
complex
half
life
occup
express
equilibrium
constant
half
live
complex
involv
induc
fit
mechan
slightli
complic
similar
rate
constant
associ
antibodi
hapten
determin
region
use
rang
k
nm
hypothet
k
half
life
first
order
decomposit
enzymeinhibitor
complex
would
minut
result
level
sensit
howev
modest
chang
k
nm
produc
new
rang
halfliv
second
k
get
smaller
correspond
stronger
bind
k
rate
get
slower
occup
time
longer
k
rate
also
determin
barrier
dissoci
drug
receptor
repres
anoth
way
optim
resid
time
inhibitor
could
captur
enough
ts
bind
affin
reliabl
give
k
pm
would
chang
half
life
rang
hour
comparison
half
live
drug
drug
candid
measur
minut
hour
coval
interact
lead
long
dissoci
half
live
case
finasterid
form
coval
bond
nadph
cofactor
activ
site
steroid
enzym
treatment
benign
prostat
hyperplasia
half
life
dissoci
complex
greater
day
noncoval
interact
also
lead
long
dissoci
half
live
natur
proteas
inhibitor
half
live
month
increas
half
live
drug
bind
repres
way
achiev
schramm
term
ultim
physiolog
goal
efficaci
maintain
target
physic
replac
bodi
benefit
long
resid
time
would
seen
reduc
dosag
result
fewer
drugdrug
interact
less
offtarget
toxic
due
lower
concentr
free
drug
serum
assum
coval
interact
abl
contribut
offtarget
effect
anoth
way
address
place
coval
interact
pharmaceut
agent
analys
small
molecul
make
best
drug
question
fundament
import
drug
discoveri
recent
year
databas
success
compound
subject
intens
statist
scrutini
attempt
discern
empir
metric
candid
molecul
judg
number
trend
emerg
includ
premium
high
potenc
molecular
weight
ratio
order
design
lead
compound
meet
criteria
analysi
hypothesi
suggest
use
coval
bond
strength
coval
interact
ensur
high
potenc
effort
could
place
optim
moieti
admet
specif
properti
coval
approach
also
util
bring
challeng
biolog
target
rang
small
molecul
inhibitor
mani
biolog
import
molecul
larg
well
structur
therefor
may
distribut
interact
broad
surfac
interact
need
contribut
small
amount
bind
gener
larg
cumul
affin
easili
match
small
molecul
accept
admet
properti
molecul
everi
interact
must
count
limit
number
avail
coval
interact
provid
bind
energi
need
compet
challeng
present
proteinprotein
proteindna
interact
also
enzym
process
protein
kinas
proteas
coincident
known
kinas
inhibitor
bind
atp
pocket
rather
bind
site
protein
substrat
despit
daunt
challeng
competit
atp
present
term
select
recent
exampl
inhibit
interact
thyroid
hormon
receptor
coregul
protein
demonstr
even
challeng
area
may
made
amen
use
coval
interact
instanc
suggest
requisit
keton
liber
protein
mannich
elimin
keton
irrevers
inhibitor
react
specif
surfac
cystein
residu
make
compound
act
mechan
base
inhibitor
area
particular
current
interest
particularli
area
cancer
therapi
hdac
inhibitor
enzym
catclyz
deacetyl
histon
involv
control
access
nuclear
dna
activ
site
long
tube
zinc
ion
activ
site
far
end
tube
like
natur
activ
site
limit
surfac
area
avail
noncoval
interact
without
also
capit
interact
surfac
surround
entranc
bind
site
use
enzym
select
bind
protein
substrat
small
molecul
shape
surfac
area
even
increas
lipophil
recent
approv
vorinostat
show
dramat
drop
bind
coval
metal
bind
hydroxam
group
remov
latter
two
exampl
highlight
key
challeng
coval
inhibitor
achiev
select
reaction
free
cystein
zinc
contain
enzym
would
catastroph
vivo
coval
interact
confer
potenc
remaind
molecul
must
use
judici
control
select
noncoval
interact
ideal
involv
involv
initi
molecular
recognit
follow
coval
bond
format
may
requir
care
select
suitabl
reactiv
group
number
socal
warhead
type
interact
make
mention
follow
tune
reactiv
moieti
form
coval
bond
kinet
bind
event
well
strength
interact
final
achiev
must
examin
care
design
optim
coval
inhibitor
propos
use
coval
interact
implicit
ration
design
inhibitor
transit
state
analogu
drug
classifi
tsa
includ
anticanc
agent
pentostatin
deoxycoformycin
hiv
proteas
inhibitor
saquinavir
influenza
drug
oseltamivir
zanamivir
shown
vast
major
enzym
involv
coval
partial
coval
interact
effect
strong
bind
affin
transit
state
employ
coval
interact
inhibit
constant
tsa
could
principl
becom
compar
ts
bind
constant
k
tx
unfortun
proven
case
field
histori
nearli
year
yet
even
best
tsa
k
picomolar
rang
previou
comparison
enzym
k
tx
k
tsa
show
k
tx
k
question
tsa
abl
take
full
advantag
bind
affin
reflect
k
tx
constant
put
two
main
problem
imperfect
ts
analog
term
geometri
electrostat
inher
inabl
ground
state
reproduc
certain
paramet
partial
bond
hyperpolar
state
sinc
howev
percept
promis
wane
extent
recent
review
irrevers
proteas
inhibitor
note
dismay
strong
bia
irrevers
inhibitor
exist
pharmaceut
industri
uphil
battl
get
irrevers
inhibitor
consid
potenti
clinic
candid
howev
mani
frequent
use
nontox
drug
found
irrevers
inhibitor
long
use
penicillin
aspirin
indic
drug
act
manner
dismiss
hand
discuss
introduct
perspect
outlook
coval
drug
may
favor
near
futur
great
effort
also
devot
develop
revers
coval
inhibitor
especi
proteas
natur
nucleophil
residu
alreadi
prime
addit
inhibitor
kind
usual
electrophil
function
group
aldehyd
revers
form
hemiacet
exampl
serin
hydroxyl
cystein
thiol
group
revers
natur
boron
ester
format
also
exploit
replac
aldehyd
inhibitor
led
clinic
approv
compound
bortezomib
use
treatment
multipl
myeloma
format
revers
coval
bond
increas
bind
affin
proteas
time
although
much
work
devot
design
revers
coval
inhibitor
serin
proteas
translat
inform
market
drug
proven
difficult
metabol
instabl
low
select
slow
kinet
bind
invok
explan
howev
andrew
et
al
shown
reactiv
pharmacokinet
profil
tune
make
accept
drug
candid
remov
entir
electrophil
isoster
drop
affin
picomolar
nanomolar
rang
indic
import
reactiv
speci
bind
use
metal
pharmaceut
pursuit
abund
preced
compound
known
interact
dna
enzym
potenti
metal
ion
form
coval
ionic
bond
make
appeal
alreadi
sever
promin
compound
either
contain
metal
themselvessuch
antineoplast
agent
cisplatin
interact
metal
complex
targetsuch
antihypertens
angiotensin
convert
enzym
inhibitor
captopril
proven
success
drug
tsa
howev
inhibitor
appear
access
full
strength
coval
interact
produc
subpicomolar
k
reason
like
inadequaci
tsa
especi
inabl
reproduc
hyperpolar
transit
state
stabl
ground
state
metal
still
excit
prospect
therapeut
compound
sinc
thermodynam
kinet
benefit
observ
class
zincchel
inhibitor
complex
activ
site
ser
serin
proteas
inclus
zinc
found
give
ad
kcalmol
bind
affin
rais
bind
constant
order
magnitud
led
k
ten
picomolar
nanomolar
rang
compound
also
exhibit
rel
long
half
live
ei
complex
hour
compound
also
highli
specif
best
one
k
four
order
magnitud
smaller
tryptas
compar
two
serin
proteas
trypsin
thrombin
strength
bind
afford
coval
drug
may
advantag
case
target
specif
suggest
infecti
diseas
target
may
replic
quickli
increas
resid
time
coval
drug
factor
howev
other
see
bacteri
viral
parasit
diseas
golden
opportun
irrevers
inhibitor
design
part
drug
administ
short
period
time
therebi
reduc
offtarget
toxic
viral
proteas
recogn
excel
drug
target
essenti
viru
replic
provid
opportun
specif
exogen
origin
mechanismbas
inhibitor
believ
less
suscept
resist
sinc
target
catalyt
essenti
residu
transit
state
analogu
saquinavir
antihiv
proteas
drug
coval
act
sar
coronaviru
proteas
inhibitor
also
shown
promis
efficaci
coval
act
drug
repres
path
toward
ultim
physiolog
inhibit
benefit
evalu
casebycas
basi
appear
excel
candid
block
proteinprotein
interact
may
less
ideal
target
exampl
gprotein
coupl
receptor
repres
signific
proport
drug
target
subject
traffick
process
intern
place
cell
membran
either
recycl
back
degrad
turnov
may
make
gpcr
unattract
candid
coval
drug
yet
anticoagul
clopidogrel
act
irrevers
inhibit
gpcr
platelet
note
earlier
enzymet
bind
use
coval
interact
achiev
bind
constant
exceed
readili
attain
noncoval
interact
case
may
numer
unreason
expect
even
inhibitor
also
use
coval
bond
might
achiev
substanti
tighter
bind
decid
particular
target
suit
coval
inhibit
varieti
develop
tool
experiment
comput
arriv
inhibitor
cravatt
colleagu
review
use
activ
sitedirect
coval
probe
activ
base
probe
activ
base
protein
profil
abpp
coval
interact
core
group
base
mechan
given
enzym
may
use
exampl
probe
proteom
phenotyp
enzym
subtyp
diseas
state
assign
function
unclassifi
protein
field
enzym
inhibitor
abpp
use
investig
select
profil
coval
act
inhibitor
bortezomib
abp
would
form
ideal
nucleu
creation
structurebas
targetspecif
compound
librari
screen
done
famili
quinic
acid
deriv
coordin
calcium
ion
among
group
bind
site
eselectin
similar
librari
could
creat
metalchel
group
sulfonamid
access
strong
bind
potenti
metalenzym
interact
abp
metal
would
help
ensur
potenc
virtu
coval
partial
coval
interact
allow
concert
focu
specif
optim
rest
molecul
comput
chemistri
tool
skelgen
bomb
use
grow
function
group
coval
interact
group
silico
evalu
bind
energi
provid
anoth
rout
ration
design
coval
dock
program
also
develop
may
bind
orient
coval
interact
drug
easier
predict
given
constraint
known
interact
bind
site
combin
quantum
mechanicalmolecular
mechan
calcul
use
calcul
prefer
bind
orient
coval
inhibitor
fatti
acid
amid
hydrolas
pure
quantum
mechan
method
use
calcul
reactiv
substitut
nitril
thiol
shown
correl
format
coval
adduct
activ
site
cystein
residu
cathepsin
k
tool
would
equal
applic
fulli
coval
interact
partial
coval
interact
metal
chelat
although
prospect
ration
design
coval
interact
core
subsequ
optim
specif
mention
two
step
need
occur
order
revers
alreadi
done
antibodi
small
molecul
case
ration
design
coval
bond
format
came
specif
ensur
work
preoptim
antibodi
one
case
known
drug
scaffold
paul
find
enzym
provid
bind
complement
shape
characterist
transit
state
provid
principl
design
revers
noncoval
inhibitor
pharmaceut
industri
aim
perspect
articl
present
discuss
limit
noncoval
bind
recent
discoveri
origin
enorm
catalyt
acceler
usual
manifest
enzym
catalysi
complementar
propos
paul
account
acceler
order
magnitud
enzym
exceed
profici
enzym
profici
achiev
kcalmol
transit
state
bind
mere
concaten
noncoval
effect
partial
coval
bond
format
enzym
cofactor
transit
state
involv
chang
mechan
aqueou
solut
involv
partial
coval
bond
requir
profici
enzym
form
actual
coval
intermedi
substrat
bond
partial
coval
ionic
case
metal
ion
associ
enzym
coordin
substrat
partli
coval
case
proton
transfer
enzym
substrat
gener
acidbas
catalysi
discuss
illustr
noncoval
interact
approxim
estim
surfac
area
small
ligand
order
design
druglik
inhibitor
high
receptor
affin
coval
interact
consid
interact
alon
automat
lead
subpicomolar
bind
affin
k
magnitud
achiev
without
goal
perspect
emphas
potenti
role
coval
bond
ration
drug
design
summari
typic
bind
constant
hostguest
complex
class
bind
distribut
repres
ideal
normal
distribut
curv
normal
area
maximum
occur
averag
valu
k
standard
deviat
use
set
width
curv
reprint
permiss
refer
copyright
amer
chemic
societi
